KR20160081172A - Skin external composition for anti-anging comprising catechins and icariside b2 - Google Patents

Abstract

The present invention relates to a composition for external applications to the skin, containing low concentrations of catechin and icariside B2 at optimal concentrations. The composition for external applications to the skin has excellent skin anti-aging effects, more specifically, antioxidant effects, effects in promoting collagen synthesis, effects in improving skin elasticity, and effects in reducing skin wrinkles.

Description

(SKIN EXTERNAL COMPOSITION FOR ANTI-ANGING COMPRISING CATECHINS AND ICARISIDE B2)

The present invention relates to a skin solvent composition containing catechin and icaricide B2 and having excellent anti-aging effect.

Human skin is the primary protective membrane of the human body. It functions to protect the internal organs from external environmental stimuli such as changes in temperature and humidity, ultraviolet rays, and pollutants. Depending on various internal and external factors, It undergoes change. In other words, internally, secretion of various hormones that regulate metabolism is reduced, the function of immune cells and the activity of cells are lowered, and the biosynthesis of immune proteins and biocompatible proteins necessary for the living body is reduced, and ozone layer destruction As the content of ultraviolet rays reaching the surface of the sunlight increases and environmental pollution is further intensified, free radicals and active noxious oxygen are increased, so that the thickness of the skin decreases, the wrinkles increase, the elasticity decreases Skin color is grayish, skin troubles are frequent, spots, freckles and black spots are increased, bleeding is poor, skin tone is getting dark, and so on.

In order to prevent the change of the skin condition due to the intrinsic and extrinsic factors, and to maintain a healthy skin condition, physiologically active substances obtained from various known animals, plants, microorganisms and the like are added to cosmetics to improve the skin condition There has been effort for.

On the other hand, the icari seed B2 is a perennial plant belonging to the fern-tail gosarit family ( Asplenium Interface Variable Name Carcinoid derived from a portion of scolopendrium) (isolated from terpenoid) component, or chemically synthesized can also (Natural Product Sciences, 14 (4 ): 265-268 (2008)). As to the icaricide compound icaride II (icariside II), whitening activity is already known (International Patent Publication No. WO 2008/035918, published on Mar. 27, 2008). On the other hand, the studies on icaricide B2, which is an icaricide compound, are insignificant, and there has not yet been reported remarkable research results on the efficacy shown in relation to the improvement of the skin condition and the synergistic effect through combination with other ingredients.

Korean Patent Laid-Open No. 10-2012-0083943 (published on July 27, 2012) International Patent Publication No. WO 2008/035918 (published on Mar. 27, 2008)

Natural Product Sciences, 14 (4): 265-268 (2008)

The present invention provides a composition for external application for skin, which contains an optimal content ratio of low concentration catechin and icaricide B2 to provide skin antiaging effect, specifically, antioxidative effect, collagen synthesis promoting effect, skin elasticity improvement effect and skin wrinkle improvement effect do.

In order to achieve the above object, the present invention provides a composition for external skin application for anti-aging comprising low-concentration catechin and icaricide B2 as an active ingredient. Specifically, the composition for external application for skin comprises 0.001 To 0.2% by weight based on the total weight of the composition, and the content ratio of the catechin: icaricide B2 is 1:25 to 1:50 in molar ratio.

INDUSTRIAL APPLICABILITY The composition for external application for skin according to the present invention has an excellent anti-aging effect by optimally containing catechin and icaricide B2 at a low concentration and increases collagen biosynthesis in the dermis to maintain a resilient and healthy skin condition, .

Hereinafter, the present invention will be described in more detail.

The catechins used in the present invention were extracted from green tea and mainly composed of EGCG, GCG, ECG and CG, but not limited to the above catechins.

Camellia sinensis ) is an evergreen tree of Camelliaceae. It is generally called green tea because its shoots or leaves are processed without fermentation during the manufacturing process. It has been reported that green tea was drunk from the new agriculture of China in 2700 BC, and it is said that Korea drank tea from the time of Silla Dynasty. In addition, green tea contains catechin, flavonoid, theanine, GABA, caffeine, tannin, and various vitamins, so it can be used for anticancer, antioxidant, antibacterial, deodorant, blood pressure Depression, and immune function are known to have a variety of effects, such as recently reported to be effective in dieting. Particularly, catechin is a major functional ingredient of green tea which exhibits various pharmacological actions ranging from antioxidant, anticancer, antibacterial, and prevention of heart disease.

The catechins contained in green tea were catechin (CA), epicatechin (EC), epigallocatechin (EGC), EGCG, and epigallocatechin (EGC) have.

In the present invention, the catechin is selected from the group consisting of EGCG (epigallocatechin gallate), GCG (gallocatechin gallate), ECG (epicatechin gallate), CG (catechin gallate), EGC (epigallocatechin) ), (-) EC (epicatechin), (+) EC (epicatechin), (-) CA (catechin) and (+) CA. The green tea extract is preferably extracted from green tea leaves, ) EGCG.

The content of catechin in the composition is 0.001 to 0.2% by weight based on the total weight of the composition, based on in vitro and in vivo experiments. If the content is less than 0.001% by weight, acting as an active ingredient is difficult to expect. If the content exceeds 0.2% by weight, the symptom improvement effect is rather reduced.

The icaricide B2 used in the present invention has a structure represented by the following formula (1).

[Chemical Formula 1]

The icaricide B2 of the present invention may be extracted from plants, synthesized according to methods known in the art, or commercially available ones may be used.

The content of the icaricide B2 is 1.0-10% by weight based on the total weight of the composition, based on in vitro and in vivo experiments. If the content is less than 1.0% by weight, it is difficult to expect the action as an active ingredient. If the content is more than 10% by weight, the symptom improvement effect is weak.

The composition for external application for skin according to the present invention can effectively improve the symptoms such as wrinkles and elasticity by using catechin and icaricide B2.

The composition for external application for skin according to the present invention contains catechin and icaricide B2 in a low concentration at a certain component ratio, that is, catechin in an amount of 0.001 to 0.2% by weight, catechin: icaricide B2 in a molar ratio of 1:25 to 1:50 The skin aging effect is more excellent.

The composition for external application for skin for anti-aging according to the present invention is characterized by being anti-aging.

The composition for external application for skin for anti-aging according to the present invention is characterized in that it is for promoting collagen synthesis.

Further, the composition for external application for skin for anti-aging according to the present invention is characterized by being for improving skin elasticity.

Further, the composition for external application for skin for anti-aging according to the present invention is characterized in that it is for improving skin wrinkles.

The above anti-aging dermatological composition of the present invention can be formulated as a cosmetic composition, and can be formulated containing a cosmetically or dermatologically acceptable medium or base. These are all formulations suitable for topical application, for example as a solution, a gel, a solid, a paste anhydrous product, an emulsion obtained by dispersing an oil phase in water, a suspension, a microemulsion, a microcapsule, a microgranule or an ionic form (liposome) In the form of ionic fibrin dispersions, or in the form of creams, skins, lotions, powders, ointments, sprays or conical sticks. It can also be used in the form of a foam or in the form of an aerosol composition further containing a compressed propellant. These compositions may be prepared according to conventional methods in the art.

The cosmetic composition according to the present invention can be applied to cosmetics such as softening agents, convergent lotion, nutritional lotion, nutritional cream, massage cream, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, pack, powder, body lotion, body cream, And body essence.

In addition, the composition according to the present invention may further comprise at least one selected from the group consisting of fatty substances, organic solvents, solubilizers, thickening agents, gelling agents, softening agents, antioxidants, suspending agents, stabilizing agents, Such as fillers, emulsifiers, emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blockers, moisturizers, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or any other ingredient commonly used in cosmetics May contain adjuvants commonly used in the field of cosmetics or dermatology. Such adjuvants are introduced in amounts commonly used in the cosmetics or dermatological fields.

In addition, the composition of the present invention may contain a skin absorption promoting substance to increase the skin improving effect.

Hereinafter, the present invention will be described in more detail with reference to examples and test examples, but the present invention is not limited to these examples.

[Referential Example 1]

The (-) epigallocatechin (EGCG) for testing the efficacy of the composition of the present invention was purchased from Sigma-Aldrich.

[Reference Example 2]

Icaricid B2 for testing the efficacy of the composition of the present invention was purchased from Simagchem Corporation (China).

 [Referential Example 3]

(-) EGCG in Reference Example 1 and 5 mL of distilled water were mixed to prepare 6 (2) standard solutions of (-) EGCG 2 μM. 0.5 μM, 0.4 μM, 0.2 μM, 0.1 μM and 0.01 μM (-) EGCG standard solutions were prepared by adding 15 mL, 20 mL, 45 mL, 95 mL and 995 mL of distilled water to five of the prepared 2 μM standard solutions.

 [Reference Example 4]

192 mg of icaricide B2 in Reference Example 2 and 5 ml of distilled water were mixed to prepare three 100 쨉 M standard solutions of icaricide B2. 45 mL and 495 mL of distilled water were added to two of the prepared 100 μM standard solutions, respectively, to prepare 10 μM and 1 μM icariside B2 standard solution.

 [Test Example 1] Inhibitory effect on reactive oxygen species (ROS) production

5 × 10 ⁴ keratinocytes (cell line: HaCaT; available from ATCC) were added to each well of a 24-well plate containing keratinocyte growth media (Clonetics, BioWhittacker, MD, USA) And adhered for 24 hours. After 16 hours, (-) EGCG was treated with 0.001 μM. For comparison, the control group did not treat (-) EGCG and paracodisol for comparison. After 2 hours, the culture solution was removed, and 100 μl of phosphate buffered saline (PBS) was added to each well. This keratinocyte was irradiated with ultraviolet rays of 30 mJ / cm 2 using an ultraviolet B (UVB) lamp (Model: F15T8, UV B 15 W, Sankyo Dennki, Japan), and then PBS was removed. Was added. The (-) EGCG was treated again and the amount of reactive oxygen species increased by ultraviolet stimulation was determined at certain time intervals. The amount of ROS was determined by reference to Tan's method of measuring the fluorescence of DCF-DA (dichlorofluorescin diacetate) oxidized by ROS (Tan et al., 1998, J. Cell Biol. Vol. 141, pp1423-1432).

At this time, for comparison, the amounts of active oxygen species were measured without treatment of the test substance (untreated), with no ultraviolet stimulation, and with ultraviolet stimulation without treatment of the test substance.

 The above procedures were carried out using the standard solutions of Reference Example 3 (concentrations 2 μM, 0.5 μM, 0.4 μM, 0.2 μM, 0.1 μM and 0.01 μM) as the above test substances. (Concentrations of 1 μM, 10 μM and 100 μM), respectively. These results are shown in the following Table 1 as a ratio to the ROS of the untreated group not treated with the test substance and not irradiated with ultraviolet light.

Test substance UVB 30 mJ / cm ² Time elapsed after investigation 0hr 2 hr 3hr No treatment 100 245 289 UVB + no treatment 100 327 383 UVB + (-) EGCG 0.01 μM 100 323 378 UVB + (-) EGCG 0.1 μM 100 321 372 UVB + (-) EGCG 0.2 [mu] M 100 318 364 UVB + (-) EGCG 0.4 [mu] M 100 311 359 UVB + (-) EGCG 0.5 [mu] M 100 310 354 UVB + (-) EGCG 2 [mu] M 100 295 342 UVB + icaricide B2 1 μM 100 320 376 UVB + icaricide B2 10 μM 100 310 357 UVB + icaricide B2 100 μM 100 297 332

In the results shown in Table 1, catechin and icaricide B2 inhibit the production of ROS, which is known to cause skin cell damage by UV rays at a low concentration, but the antioxidative effect is almost insignificant to the amount of ROS after ultraviolet stimulation in the untreated vehicle .

In order to examine the synergistic effect on the sulfation activity of icaricide B2, the standard solutions of Reference Example 3 (concentrations 1 μM, 0.5 μM, 0.4 μM, 0.2 μM, 0.1 μM and 0.01 μM) The above procedure was carried out by mixing with the standard solution of Reference Example 4 (concentration 10 mu M).

These results are shown in the following Table 2 as a ratio to the ROS of the untreated group not treated with the test substance and not irradiated with ultraviolet light.

(-) EGCG concentration UVB 30 mJ / cm ² Time elapsed after investigation 0hr 2 hr 3hr (-) EGCG + icaricide B2 10 [mu] M 0.01 μM 100 317 375 0.1 μM 100 303 342 0.2 [mu] M 100 274 332 0.4 μM 100 253 297 0.5 [mu] M 100 252 296 1 μM 100 252 295

     As shown in Table 2, when the concentration of catechin is less than 0.2 μM, the effect of inhibiting ROS is weak. When the concentration of catechin is less than 0.4 μM, : The optimum content ratio of icaricide B2 was found to be 1: 25 ~ 1: 50 based on the molar concentration ratio. It was confirmed that the synergy effect of antioxidant was superior to that of catechin and icaricide B2 alone.

 [Test Example 2] Measurement of collagen biosynthesis efficiency of skin cells

Human fibroblast (cell line: KF-4109; available from Klebosaur) was added to a 48 well microtiter plate containing 2.5% fetal bovine serum-containing DMEM (Dulbecco's Modified Eagle's Media) after incubation for 10 into the ^four levels, it was replaced with medium containing the test substance. After 48 hours of incubation, the supernatant was harvested and the amount of procollagen produced was quantitated using the ELISA (Takara MK101) method.

The above procedures were carried out using the standard solutions of Reference Example 3 (concentrations 2 μM, 0.5 μM, 0.4 μM, 0.2 μM, 0.1 μM and 0.01 μM) as the above test substances. (Concentrations of 1 μM, 10 μM and 100 μM), respectively. These results are shown in Table 3, where the control group without any treatment is designated as 100, and the comparative values are shown in Table 3 below.

density Amount of collagen production (-) EGCG 0.01 μM 125.7 0.1 μM 133.8 0.2 [mu] M 147.4 0.4 μM 154.6 0.5 [mu] M 155.8 2 [mu] M 156.7 Icari seed B2 1 μM 100.5 10 μM 128.7 100 μM 156.9

It can be seen from Table 3 that catechin and icaricide B2 increase collagen biosynthesis even at low concentrations, but the effect is weak.

In order to examine the synergistic effect on the collagen biosynthesis of icaricide B2, standard solutions (concentration 1 μM, 0.5 μM, 0.4 μM, 0.2 μM, 0.1 μM and 0.01 μM) of Reference Example 3 were added to the above test materials The above procedure was carried out by mixing with the standard solution of Reference Example 4 (concentration 10 mu M).

These results are shown in the following Table 4 as a control group in which no treatment is performed.

(-) EGCG concentration Amount of collagen production (-) EGCG + icaricide B2 10 [mu] M 0.01 μM 145.8 0.1 μM 157.3 0.2 [mu] M 160.1 0.4 μM 168.4 0.5 [mu] M 168.9 1 μM 169.1

As shown in Table 4, when the concentration of catechin is less than 0.2 μM, the amount of collagen produced is weak. When the concentration of catechin is less than 0.4 μM, The optimal content ratio of seed B2 was found to be 1: 25 ~ 1: 50 as a molar concentration ratio. It was confirmed that the synergistic effect of collagen biosynthesis was superior to that of catechin and icaricide B2 alone.

 [Test Example 3] Wrinkle improvement effect in human

The nutritional creams prepared in the compositions of Comparative Examples 1 to 4 and Examples 1 to 4 in Table 5 were evaluated as follows to evaluate the wrinkle-improving effect. 80 women in their 30s were divided into 10 groups of 10 persons each in Comparative Examples 1 to 4 and Examples 1 to 4, and applied once a day for 8 weeks. Then, the replicas were removed using silicone and the wrinkles were measured with a visiometer, SV600, Courage + Khazaka electronic GmbH, Germany). The results are shown in Table 6 below. The values in Table 6 below are the average values obtained by subtracting the pre-application parameter values from the respective parameter values after 8 weeks of application.

Compounding ingredient
(Content:% by weight) Example 1 Example 2 Example 3 Example 4 Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Purified water To 100 To 100 To 100 To 100 To 100 To 100 To 100 To 100 (-) EGCG 0.03 0.07 0.06 0.04 0.03 0.07 - - Icari seed B2 1.47 1.43 1.44 1.46 - - 1.43 1.47 Vegetable hydrogenated oil 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 Stearic acid 0.60 0.60 0.60 0.60 0.60 0.60 0.60 0.60 Glycerol stearate 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Stearyl alcohol 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 Polyglyceryl-10pentastearate and behenyl alcohol and sodium stearoyl lactylate 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Arachidyl behenyl alcohol and arachidyl glucoside 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 Cetylaryl Alcohol and Cetearyl Glucose Side 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 PEG-100 Stearate & Glycerololate & Propylene Glycol 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 Caprylic / capric triglyceride 11.0 11.0 11.0 11.0 11.0 11.0 11.0 11.0 Cyclone methicone 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0 Preservative, incense Suitable amount Suitable amount Suitable amount Suitable amount Suitable amount Suitable amount Suitable amount Suitable amount Triethanolamine 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1

Clinical results after 8 weeks of use R1 R2 R3 R4 R5 Example 1 -0.22 -0.23 -0.18 -0.04 -0.04 Example 2 -0.24 -0.24 -0.19 -0.06 -0.05 Example 3 -0.23 -0.25 -0.18 -0.06 -0.04 Example 4 -0.25 -0.24 -0.19 -0.06 -0.03 Comparative Example 1 -0.16 -0.17 -0.13 -0.04 -0.03 Comparative Example 2 -0.16 -0.17 -0.12 -0.05 -0.03 Comparative Example 3 0.26 0.25 0.22 0.04 0.04 Comparative Example 4 0.24 0.24 0.17 0.05 0.04 * R1: Difference between the maximum value and the minimum value of the contour line
R2: The wrinkle contour line is arbitrarily divided into 5 squares, and the average of R1 values
R3: Maximum value of R1 divided by 5
R4: Average value obtained by subtracting the value of each apex and valley from the baseline of the wrinkle contour line
R5: Difference between the baseline of the wrinkle contour line minus the contour of each wrinkle

As shown in Table 6, it was found that the external-use composition of Examples 1 to 4 prepared by containing both catechin and icaricide B2 in a certain component ratio was excellent in the effect of improving skin wrinkles.

 [Test Example 4] Measurement of skin elasticity improvement in human body

The skin elasticity improvement effect of the nutrition cream prepared with the composition of Table 5 was measured. 80 healthy women over 30 years old at a temperature of 24-26 캜 and a humidity of 75% were divided into 10 groups and the nutritional creams of Comparative Examples 1 to 4 and Examples 1 to 4 were applied to the face for 2 weeks for 12 weeks in each group The skin elasticity was measured using a skin elasticity meter Cutometer SEM 575, C + K Electronic Co., Germany). The results are shown in Table 6. The results in Table 7 are expressed as the value of ΔR8 of the skin elasticity meter Cutometer SEM 575, and the value of R8 indicates the property of viscoelasticity.

At the end of the test, subjects were asked to fill out questionnaires and perform subjective evaluation of efficacy at the same time. The results are shown in Table 8 below.

Application group Skin elasticity effect Example 1 0.37 Example 2 0.43 Example 3 0.41 Example 4 0.45 Comparative Example 1 0.29 Comparative Example 2 0.31 Comparative Example 3 0.28 Comparative Example 4 0.39

Application group Number of respondents (in) Very good Good usually Inadequate Example 1 4 3 2 One Example 2 4 4 One One Example 3 4 3 3 0 Example 4 3 5 One One Comparative Example 1 One One 6 2 Comparative Example 2 One 2 4 3 Comparative Example 3 One 2 4 3 Comparative Example 4 One One 5 3

As shown in Table 7, in the group to which the compositions of Examples 1 to 4 containing low-concentration catechin and icaricide B2 were applied, skin elasticity was further increased as compared with the group to which the comparative example was applied.

On the other hand, through the questionnaire, it was also confirmed that when the compositions according to the present invention, Examples 1 to 4, were applied, skin elasticity was improved.

Hereinafter, formulation examples of the composition according to the present invention will be described. However, the pharmaceutical composition and the cosmetic composition can be applied to various formulations, and the present invention is not limited thereto but is specifically described.

[Formulation Example 1] Lotion

Lotions are prepared according to a conventional method with the composition shown in Table 9 below.

Content (% by weight) (-) EGCG 0.04 Icari seed B2 2.46 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 PEG 12 nonyl phenyl ether 0.2 Polysorbate 80 0.4 ethanol 10.0 Triethanolamine 0.1 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 2] Nourishing cream

Nutritive creams are prepared according to the usual methods with the compositions shown in Table 10 below.

Content (% by weight) (-) EGCG 0.04 Icari seed B2 2.46 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 PEG 60 hardened castor oil 2.0 Liquid paraffin 10.0 Squalane 5.0 Caprylic / caproic triglyceride 5.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 3] Massage cream

A massage cream is prepared according to a conventional method with the composition shown in Table 11 below.

Content (% by weight) (-) EGCG 0.04 Icari seed B2 2.46 Wax 10.0 Polysorbate 60 1.5 PEG 60 hardened castor oil 2.0 Sorbitan sesquioleate 0.8 Liquid paraffin 40.0 Squalane 5.0 Caprylic / capric triglyceride 4.0 glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 4] Pack

A pack is prepared according to a conventional method with the composition shown in Table 12 below.

Content (% by weight) (-) EGCG 0.04 Icari seed B2 2.46 Polyvinyl alcohol 13.0 Sodium carboxymethylcellulose 0.2 glycerin 5.0 Allantoin 0.1 ethanol 6.0 PEG 12 nonyl phenyl ether 0.3 Polysorbate 60 0.3 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 5] Gel

A gel is prepared according to a conventional method with the composition shown in Table 13 below.

Content (% by weight) (-) EGCG 0.02 Icari seed B2 1.48 Ethylenediamine sodium acetate 0.05 glycerin 5.0 Carboxyvinyl polymer 0.3 ethanol 5.0 PEG 60 hardened castor oil 0.5 Triethanolamine 0.3 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 6] Ointment

Ointments were prepared in a conventional manner at the compositions listed in Table 14 below.

Content (% by weight) (-) EGCG 0.02 Icari seed B2 1.48 glycerin 8.0 Butylene glycol 4.0 Liquid paraffin 15.0 Beta Glucan 7.0 Carbomer 0.1 Caprylic / capric triglyceride 3.0 Squalane 1.0 Cetearyl glucoside 1.5 Sorbitan stearate 0.4 Cetearyl alcohol 1.0 Wax 4.0 Preservative, coloring, fragrance Suitable amount Purified water Balance

[Formulation Example 7] Soft capsule

(-) EGCG, 2.46 mg of icaricide B2, 2.5 mg of vitamin C, 2 mg of palm oil, 8 mg of palm kernel oil, 4 mg of yellow radish and 6 mg of lecithin were mixed and 400 mg per capsule was filled in accordance with a conventional method to prepare a soft capsule Respectively.

[Formulation Example 8] Tablets

(-) EGCG, 2.46 mg of icaricide B2, 2.5 mg of vitamin C, 100 mg of glucose, 96 mg of starch and 4 mg of magnesium stearate and 40 mg of 30% ethanol was added to form granules, followed by drying at 60 ° C, And then the tablet was tableted.

[Formulation Example 9]

(-) EGCG, 147 mg of icaricide B2, 150 mg of vitamin C, 100 mg of glucose, and 600 mg of starch were mixed and 100 mg of 30% ethanol was added thereto to form granules, followed by drying at 60 ° C to form granules. Lt; / RTI > The final weight of the contents was 1 g.

[Formulation Example 10]

(-) EGCG, 2.46 mg of icaricide B2, 2.5 mg of vitamin C, 10 g of glucose, 2 g of citric acid and 187.8 g of purified water were mixed and filled in a bottle. The final volume of the contents was adjusted to 200 ml.

While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. something to do. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (6)

Catechin and an icaricide B2 represented by the following formula 1 as an active ingredient,
The catechin is contained in an amount of 0.001 to 0.2% by weight based on the total weight of the composition, the icaricide B2 is contained in an amount of 1.0 to 10% by weight based on the total weight of the composition,
Wherein the content ratio of the catechin: icaricide B2 is 1:25 to 1:50 by molar ratio.
[Chemical Formula 1]

The catechin according to claim 1, wherein the catechin is at least one selected from the group consisting of EGCG (epigallocatechin gallate), GCG (gallocatechin gallate), ECG (epicatechin gallate), and CG Wherein the composition is an external preparation for skin. The composition for external application for skin according to claim 1, wherein the composition is for antioxidation. The composition for external application for skin according to claim 1, wherein the composition is for promoting collagen synthesis. The composition for external application for skin according to claim 1, wherein the composition is for improving skin elasticity. The composition for external application for skin according to claim 1, wherein the composition is for improving skin wrinkles.